- ResMed reiterated annual revenue guidance of US$5.75-5.85 billion.
Macquarie says ResMed's reiterated annual revenue guidance of US$5.75-5.85 billion implies a slight operational upgrade, given increased currency headwinds. The bank keeps outperform and lifts its target price 1.5% to A$47.50. Shares are down 7.2% at A$32.96.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.